ChoosingTherapy.com is user-supported. We may earn a commission if you sign up for a service through our links, at no cost to you. Our reviews and comparisons are based on independent research.
- Compounded tirzepatide and Zepbound share an active ingredient, but only Zepbound is FDA-approved. Compounded versions reach patients without FDA review of their safety, effectiveness, or quality.1
- Zepbound’s 72-week trial showed an average weight loss of 15.0% to 20.9% by dose, against 3.1% on placebo.2 PubMed lists no randomized trial that tested a compounded product. FDA records show more than 730 adverse event reports for compounded tirzepatide through May 31, 2026.1
- Self-pay Zepbound runs $299 to $449 a month through LillyDirect if refilled within 45 days. Some compounded sellers list less, such as $214 a month. Lilly’s savings cards and Medicare’s GLP-1 Bridge cover the brand only.3
Zepbound comes from Eli Lilly and is injected once a week. The FDA approved it for weight management in November 2023 and for sleep apnea in December 2024. Compounded tirzepatide is mixed by a pharmacy for a single patient and skips FDA review. Since 2025, pharmacies may compound it only in small volumes or with a documented clinical reason.4 Only Zepbound comes with an FDA-reviewed label, trial results, Lilly’s savings cards, and Medicare coverage.Sesame Care offers online visits with clinicians who prescribe only FDA-approved GLP-1s for weight loss, including Zepbound. The program costs from $59 a month on an annual plan, plus the cost of the drug. Discuss FDA-approved Zepbound with a Sesame Care clinician
ChoosingTherapy.com may earn a commission from the companies whose services are linked on this page.
Side-by-side comparison (October 2026)
Prices and FDA figures were checked on October 19, 2026; the HealthRx price on September 28, 2026.
| FDA approval | Weight management (2023), sleep apnea (2024) | Not approved |
| Maker | Eli Lilly, under CGMP in FDA-inspected plants | 503A pharmacy under state oversight, no CGMP |
| Ingredients | Tirzepatide and label-listed excipients only | Varies; B12, niacinamide or glycine often added |
| Forms | Pen, single-dose vial, multi-dose vial, KwikPen; all injections | Mostly multi-dose vials; unapproved tablets and sublingual forms |
| Doses | Six fixed strengths, 2.5 mg to 15 mg | Set by the prescriber; vial volumes differ |
| Trial evidence | SURMOUNT trials on the label | No randomized trial found |
| FDA reports | Boxed warning and side effects on the label | More than 730 adverse event reports by May 31, 2026, likely undercounted |
| Legal status | Prescription, not controlled | Prescription; limited 503A compounding only |
| Self-pay cost | $299 to $449 a month if refilled within 45 days | HealthRx $214 a month; Mochi Health from $90 a weekly dose plus membership; Henry Meds tablets $1,047 a plan |
| Insurance | Some commercial plans; $25 savings card; Medicare Bridge | Not on Lilly’s cards or the Medicare Bridge |
Which option fits which situation
Your prescriber decides whether tirzepatide suits you and at what dose, and the pharmacy label says how to take what you receive.
Zepbound
Zepbound may suit you if:
- You want the version the FDA reviewed, with trial results on its label
- Your commercial plan covers the single-dose pen, where Lilly’s savings card can bring a fill as low as $25 through December 31, 2026
- You’re on Medicare Part D and qualify for the GLP-1 Bridge, a $50 copay for the KwikPen through December 31, 20275
- You’re treated for moderate to severe sleep apnea with obesity, an approved use
- You’d prefer fixed doses in a prefilled pen to drawing doses from a vial
Sesame Care’s providers prescribe Zepbound pens, vials, and KwikPens when clinically appropriate and handle prior authorization for patients with commercial insurance. Prescriptions are at the provider’s discretion. See our Sesame Care review for more. Ask a Sesame Care provider whether Zepbound suits you
Compounded tirzepatide
A compounded version may suit you if:
- Your prescriber documents that an approved drug doesn’t meet your medical needs, or the case the FDA says compounding is for1
- You pay cash and value a seller’s lower listed price over FDA review, trial evidence, and coverage. The FDA flags deep discounts as a warning sign.
Is compounded tirzepatide FDA approved?
Compounded tirzepatide is not FDA-approved, so no one at the agency reviewed its safety, effectiveness, or quality.1 For Zepbound, FDA reviewers weighed Lilly’s clinical data and labeling and inspected its manufacturing sites.Zepbound and Mounjaro, Lilly’s diabetes brand, are the non-compounded forms. Our tirzepatide guide and Zepbound guide cover them.
How each product is made
Lilly makes Zepbound under current good manufacturing practice (CGMP), the FDA’s production standard. A 503A pharmacy compounds for one patient from a valid prescription. It isn’t held to CGMP and answers mainly to its state board.6 A 503B outsourcing facility follows CGMP. Tirzepatide is on neither the 503B bulk list nor the shortage list, so a 503B facility can’t compound it from bulk.4 In September 2026, the FDA warned Empower Pharmacy, a large Houston compounder, that it made sterile products under insanitary conditions.7 A 2026 JAMA Health Forum study traced compounded GLP-1s from 75 clinics in two states to 23 facilities. Four of 21 lacked a sterile compounding license.8
Added ingredients
Zepbound’s label lists tirzepatide, salts, and water. The multi-dose forms add benzyl alcohol, glycerin, and phenol. None contain vitamin B12, niacinamide, or glycine.2 A 2026 Annals of Pharmacotherapy review found that 48% of compounded semaglutide and tirzepatide products online added B12, glycine, niacinamide, docusate or ondansetron. The authors found little rationale for the nutrient add-ins.9 The FDA’s Empower letter treated that pharmacy’s tirzepatide and niacinamide injections as essentially copies of the approved drugs, with differences that looked pretextual.7 Lilly scientists reported an impurity formed when tirzepatide reacts with certain forms of B12. Its clinical effects are unknown.10
Dose forms
Zepbound’s single-dose pen and vial hold one 0.5 mL dose; the KwikPen and multi-dose vial each hold four 0.6 mL doses.2
How doses are set
The Zepbound label starts at 2.5 mg weekly and steps up by 2.5 mg no sooner than every 4 weeks, to a 15 mg maximum.2 No FDA label gives a dose for compounded tirzepatide; the pharmacy prints the prescribed amount as a volume. In August 2026, the FDA gave the example of a 17 mg/mL vial, where 2.5 mg is 0.15 mL. It said those volumes are not interchangeable with Zepbound’s.11 Patients have also complained to the FDA about vials with well over four weeks of drug. The FDA suggests labels say to discard a vial after the 4th weekly injection.11
Tablets and under-the-tongue forms
Every approved tirzepatide product is an injection. The Annals review found compounded tablets and sublingual forms and said any advantage over approved GLP-1 pills hasn’t been determined.9 Henry Meds’ only tirzepatide product is a compounded dissolving tablet taken daily.
Does compounded tirzepatide work as well as Zepbound?
Compounded tirzepatide isn’t proven to work as well as Zepbound, because only Lilly’s product was tested in the published trials. Henry Meds’ disclosure warns against judging compounded medications by trials of approved drugs.Tirzepatide activates GIP and GLP-1 receptors, which help regulate appetite. Its half-life is about 5 days.2 The FDA doesn’t verify that a compounded product holds that molecule at its stated strength.The SURMOUNT-1 trial followed 2,539 adults without diabetes for 72 weeks. Alongside diet and exercise, those on Zepbound lost an average of 15.0% to 20.9% of body weight, versus 3.1% for placebo. In two sleep apnea trials, breathing interruptions per hour fell by about half or more.2
Safety reports and known risks
The FDA’s count of adverse event reports for compounded tirzepatide had passed 730 by May 31, 2026. Federal law doesn’t require 503A pharmacies to report, so the FDA expects underreporting. Many reports describe side effects already known from the approved drugs.1 Some may be linked to doses above the approved label. Some hospitalizations reported to the FDA may stem from dosing errors with compounded semaglutide vials. The FDA also warns about injections that arrive warm and fake labels naming pharmacies that don’t exist.1 A 2026 study of the FDA’s reporting database found compounded GLP-1s had higher reporting odds for hospitalization, contamination, and suicidality than non-compounded ones. The study shows an association and can’t prove cause.12 Zepbound’s boxed warning concerns thyroid C-cell tumors, which tirzepatide caused in rats. The label bars its use with a personal or family history of medullary thyroid cancer or MEN 2. Pancreatitis and gallbladder disease are also label warnings, and nausea and diarrhea are common.2 These risks come from tirzepatide itself, so they apply to either version. Report problems to the FDA’s MedWatch at 1-800-FDA-1088.This article is for information only and is not medical advice. Talk to a doctor or licensed clinician before starting, stopping, or changing any treatment. If your mood worsens or you have thoughts of harming yourself, call or text 988 for the Suicide and Crisis Lifeline. For a medical emergency, call 911.
Legal availability in 2026
The FDA found the tirzepatide shortage resolved in October 2024 and reaffirmed that in December. Compounders’ grace periods for copies ran out in March 2025.4 A 503A pharmacy may still compound for a patient whose prescriber documents a significant difference from Zepbound. For now, the FDA tolerates up to four copy prescriptions per pharmacy each month.4On April 30, 2026, the FDA proposed excluding tirzepatide from the 503B bulk list; it was still a proposal on October 19, 2026.13 Either product must be filled at a state-licensed pharmacy.1 Zepbound isn’t a controlled substance, so telehealth prescribers can write it.
Cost per month and insurance
LillyDirect charges $299 a month for Zepbound 2.5 mg, $399 for 5 mg, and $449 for higher doses if refilled within 45 days. Needles are extra. The single-dose pen lists near $1,086 without coverage. Medicare’s Bridge covers only the KwikPen and excludes people with type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease. Their Part D plan may cover it instead.3 Through Sesame Care, the annual plan plus a 2.5 mg vial starts at $358 a month.HealthRx lists compounded injections at $193 the first month and $214 after, including clinician review. Henry Meds charges $1,047 per multi-month tablet plan, or $891 paid in full, and takes no insurance. HSA or FSA use for compounded drugs depends on your plan.Mochi Health sells both versions. Its 2025 and 2026 Trustpilot reviews mention switching to save money. Some reviewers switched to compounded doses, and one switched to the brand once Medicare covered it. Another asked for Zepbound and was prescribed compounded tirzepatide with niacinamide.
FDA-approved GLP-1 pills
The Wegovy pill (oral semaglutide) and Foundayo (orforglipron) are FDA-approved for weight loss. No tirzepatide pill is approved. Sesame Care lists both as approved options, and Hims lists each from $149 a month plus membership. Browse the FDA-approved GLP-1s on Sesame Care
Frequently Asked Questions
What is the difference between compounded tirzepatide and Zepbound?
The main difference between compounded tirzepatide and Zepbound is FDA approval. Zepbound is Lilly’s approved injection, tested in trials. Compounded tirzepatide is made by a pharmacy without FDA review, and its add-ins and form vary.
Is compounded tirzepatide the same as Zepbound?
Compounded tirzepatide is not the same as Zepbound, even when the active ingredient matches. The FDA doesn’t verify its contents.
What is the difference between tirzepatide and compounded tirzepatide?
The difference between tirzepatide and compounded tirzepatide is who makes it. Non-compounded tirzepatide means Lilly’s approved Zepbound and Mounjaro; compounded versions are mixed by pharmacies and aren’t approved.
How does compounded tirzepatide work?
Compounded tirzepatide is meant to work like Zepbound, activating GIP and GLP-1 receptors that help regulate appetite. The FDA hasn’t confirmed the strength of any compounded product.
How is compounded tirzepatide made?
A 503A pharmacy makes compounded tirzepatide from bulk ingredients for one patient’s prescription. Many products add an ingredient such as B12.
Is compounded tirzepatide safe?
Compounded tirzepatide’s safety hasn’t been reviewed by the FDA. Adverse event reports to the agency topped 730 by May 31, 2026.
How much weight do people lose on compounded tirzepatide?
Weight loss on compounded tirzepatide hasn’t been measured in a randomized trial. The 15.0% to 20.9% figures come from Zepbound’s trial.
Does insurance cover compounded tirzepatide?
Medicare’s GLP-1 Bridge doesn’t cover compounded tirzepatide, and neither do Lilly’s savings cards; both cover approved brands only. Henry Meds takes no insurance.
Can you switch from compounded tirzepatide to Zepbound?
Switching from compounded tirzepatide to Zepbound is your prescriber’s call. The FDA says compounded vial volumes aren’t interchangeable with Zepbound doses, so the prescriber sets the new dose.
Does Sesame Care prescribe compounded tirzepatide?
Sesame Care does not prescribe compounded tirzepatide. Its weight-loss program offers only FDA-approved GLP-1s, such as Zepbound and the Wegovy pill.
ChoosingTherapy.com strives to provide our readers with mental health content that is accurate and actionable. We have high standards for what can be cited within our articles. Acceptable sources include government agencies, universities and colleges, scholarly journals, industry and professional associations, and other high-integrity sources of mental health journalism. Learn more by reviewing our full editorial policy.
- U.S. Food and Drug Administration. (2026, October). FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Retrieved from: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- U.S. Food and Drug Administration. (2026, August). ZEPBOUND (tirzepatide) injection prescribing information. Retrieved from: https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22ZEPBOUND%22
- Medicare.gov. (2026, October). Weight-loss drugs. Retrieved from: https://www.medicare.gov/coverage/weight-loss-drugs
- U.S. Food and Drug Administration. (2026, April). FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Retrieved from: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- Centers for Medicare & Medicaid Services. (2026, October). Medicare GLP-1 Bridge. Retrieved from: https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
- U.S. Food and Drug Administration. (2025, September). Compounding and the FDA: Questions and Answers. Retrieved from: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- U.S. Food and Drug Administration. (2026, September). Warning letter: Empower Clinic Services, LLC dba Empower Pharmacy, 738238. Retrieved from: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026
- DiStefano MJ, Tilley A, Paratane D, et al. (2026, July). Postshortage Compounded GLP-1 RA Market in 2 States With Potentially High Demand. JAMA Health Forum. Retrieved from: https://doi.org/10.1001/jamahealthforum.2026.2207
- Belcourt J, Sapowadia A, White CM. (2026, February). Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown. Annals of Pharmacotherapy. Retrieved from: https://doi.org/10.1177/10600280261421979
- Jordan B, Arbogast L, Clemens M, Huang L, Snyder M. (2026, May). A novel, widespread impurity in mass-compounded tirzepatide/B12 products: potential patient safety implications. Expert Opinion on Drug Safety. Retrieved from: https://doi.org/10.1080/14740338.2026.2663185
- U.S. Food and Drug Administration. (2026, August). Letter to the Federation of State Medical Boards on compounded GLP-1 multiple-dose vials. Retrieved from: https://www.albme.gov/uploads/pdfs/FDA_Letter_to_FSMB_-_August_12_2026.pdf
- McCall KL, Mastro Dwyer KA, Casey RT, et al. (2026, March). Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system. Expert Opinion on Drug Safety. Retrieved from: https://doi.org/10.1080/14740338.2025.2499670
- U.S. Food and Drug Administration. (2026, April). FDA proposes to exclude semaglutide, tirzepatide and liraglutide from 503B bulks list. Retrieved from: https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
We regularly update the articles on ChoosingTherapy.com to ensure we continue to reflect scientific consensus on the topics we cover, to incorporate new research into our articles, and to better answer our audience’s questions. When our content undergoes a significant revision, we summarize the changes that were made and the date on which they occurred. We also record the authors and medical reviewers who contributed to previous versions of the article. Read more about our editorial policies here.
Author: Patricia Duggan, LCMHC
Reviewer: MD review pending